![Journal of Prescribing Practice - Dosing of mesna to avoid urothelial toxicity from cyclophosphamide infusion Journal of Prescribing Practice - Dosing of mesna to avoid urothelial toxicity from cyclophosphamide infusion](https://www.prescribingpractice.com/media/qi5p2ayx/jprp-2022-4-8-342_f01.jpg)
Journal of Prescribing Practice - Dosing of mesna to avoid urothelial toxicity from cyclophosphamide infusion
![Pharmaceuticals | Free Full-Text | Pharmacokinetics and Pharmacogenetics of Cyclophosphamide in a Neonate and Infant Childhood Cancer Patient Population Pharmaceuticals | Free Full-Text | Pharmacokinetics and Pharmacogenetics of Cyclophosphamide in a Neonate and Infant Childhood Cancer Patient Population](https://www.mdpi.com/pharmaceuticals/pharmaceuticals-14-00272/article_deploy/html/images/pharmaceuticals-14-00272-g001.png)
Pharmaceuticals | Free Full-Text | Pharmacokinetics and Pharmacogenetics of Cyclophosphamide in a Neonate and Infant Childhood Cancer Patient Population
![Reduced post-transplant cyclophosphamide doses in haploidentical hematopoietic cell transplantation for elderly patients with hematological malignancies | Bone Marrow Transplantation Reduced post-transplant cyclophosphamide doses in haploidentical hematopoietic cell transplantation for elderly patients with hematological malignancies | Bone Marrow Transplantation](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41409-022-01908-y/MediaObjects/41409_2022_1908_Fig1_HTML.png)
Reduced post-transplant cyclophosphamide doses in haploidentical hematopoietic cell transplantation for elderly patients with hematological malignancies | Bone Marrow Transplantation
![The effect of granulocyte-colony stimulating factor, decitabine, and busulfan–cyclophosphamide versus busulfan–cyclophosphamide conditioning on relapse in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia evolving from ... The effect of granulocyte-colony stimulating factor, decitabine, and busulfan–cyclophosphamide versus busulfan–cyclophosphamide conditioning on relapse in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia evolving from ...](https://www.thelancet.com/cms/attachment/36095ed8-7b85-4a20-8bc4-3ac4fa70ecad/gr1_lrg.jpg)
The effect of granulocyte-colony stimulating factor, decitabine, and busulfan–cyclophosphamide versus busulfan–cyclophosphamide conditioning on relapse in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia evolving from ...
![Comparison of Dose Adjustment Strategies for Obesity in High-dose Cyclophosphamide Among Adult Hematopoietic Cell Transplantation Recipients: Pharmacokinetic Analysis - Transplantation and Cellular Therapy, Official Publication of the American Society ... Comparison of Dose Adjustment Strategies for Obesity in High-dose Cyclophosphamide Among Adult Hematopoietic Cell Transplantation Recipients: Pharmacokinetic Analysis - Transplantation and Cellular Therapy, Official Publication of the American Society ...](https://www.astctjournal.org/cms/attachment/698908d4-81ac-4adb-b145-4a5070f2c653/ga1_lrg.jpg)
Comparison of Dose Adjustment Strategies for Obesity in High-dose Cyclophosphamide Among Adult Hematopoietic Cell Transplantation Recipients: Pharmacokinetic Analysis - Transplantation and Cellular Therapy, Official Publication of the American Society ...
![Immunological Effects of Low-dose Cyclophosphamide in Cancer Patients Treated With Oncolytic Adenovirus: Molecular Therapy Immunological Effects of Low-dose Cyclophosphamide in Cancer Patients Treated With Oncolytic Adenovirus: Molecular Therapy](https://www.cell.com/cms/attachment/cd22f0c8-1524-4c03-b666-7a80d91c712d/gr1_lrg.jpg)
Immunological Effects of Low-dose Cyclophosphamide in Cancer Patients Treated With Oncolytic Adenovirus: Molecular Therapy
![These highlights do not include all the information needed to use CYCLOPHOSPHAMIDE safely and effectively. See full prescribing information for CYCLOPHOSPHAMIDE. CYCLOPHOSPHAMIDE for injection, for intravenous useInitial U.S. Approval: 1959 These highlights do not include all the information needed to use CYCLOPHOSPHAMIDE safely and effectively. See full prescribing information for CYCLOPHOSPHAMIDE. CYCLOPHOSPHAMIDE for injection, for intravenous useInitial U.S. Approval: 1959](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=image-08.jpg&id=515396)
These highlights do not include all the information needed to use CYCLOPHOSPHAMIDE safely and effectively. See full prescribing information for CYCLOPHOSPHAMIDE. CYCLOPHOSPHAMIDE for injection, for intravenous useInitial U.S. Approval: 1959
![Comparison of Dose Adjustment Strategies for Obesity in High-dose Cyclophosphamide Among Adult Hematopoietic Cell Transplantation Recipients: Pharmacokinetic Analysis - Transplantation and Cellular Therapy, Official Publication of the American Society ... Comparison of Dose Adjustment Strategies for Obesity in High-dose Cyclophosphamide Among Adult Hematopoietic Cell Transplantation Recipients: Pharmacokinetic Analysis - Transplantation and Cellular Therapy, Official Publication of the American Society ...](https://www.astctjournal.org/cms/asset/9128c19c-393e-4e3e-90aa-ce3b3f824fc5/ga1.jpg)
Comparison of Dose Adjustment Strategies for Obesity in High-dose Cyclophosphamide Among Adult Hematopoietic Cell Transplantation Recipients: Pharmacokinetic Analysis - Transplantation and Cellular Therapy, Official Publication of the American Society ...
![Immunostimulatory and anti-tumor metronomic cyclophosphamide regimens assessed in primary orthotopic and metastatic murine breast cancer | npj Breast Cancer Immunostimulatory and anti-tumor metronomic cyclophosphamide regimens assessed in primary orthotopic and metastatic murine breast cancer | npj Breast Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41523-020-0171-1/MediaObjects/41523_2020_171_Fig1_HTML.png)
Immunostimulatory and anti-tumor metronomic cyclophosphamide regimens assessed in primary orthotopic and metastatic murine breast cancer | npj Breast Cancer
![Dosing of mesna to avoid urothelial toxicity from cyclophosphamide infusion - Journal of Prescribing Practice Dosing of mesna to avoid urothelial toxicity from cyclophosphamide infusion - Journal of Prescribing Practice](https://www.prescribingpractice.com/media/bp5fx5du/calculation_16_1000x667.jpg)
Dosing of mesna to avoid urothelial toxicity from cyclophosphamide infusion - Journal of Prescribing Practice
![Comparison of short interval and low dose (SILD) with high dose of cyclophosphamide in the susceptibility to infection in SLE: a multicentrereal-world study | Lupus Science & Medicine Comparison of short interval and low dose (SILD) with high dose of cyclophosphamide in the susceptibility to infection in SLE: a multicentrereal-world study | Lupus Science & Medicine](https://lupus.bmj.com/content/lupusscimed/9/1/e000779/F1.large.jpg)
Comparison of short interval and low dose (SILD) with high dose of cyclophosphamide in the susceptibility to infection in SLE: a multicentrereal-world study | Lupus Science & Medicine
![These highlights do not include all the information needed to use CYCLOPHOSPHAMIDE safely and effectively. See full prescribing information for CYCLOPHOSPHAMIDE. CYCLOPHOSPHAMIDE injection, for intravenous use Initial U.S. Approval: 1959 These highlights do not include all the information needed to use CYCLOPHOSPHAMIDE safely and effectively. See full prescribing information for CYCLOPHOSPHAMIDE. CYCLOPHOSPHAMIDE injection, for intravenous use Initial U.S. Approval: 1959](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=cyclophosphamide-for-injection-usp-2.jpg&id=606181)